NYSE · ABT

Abbott Laboratories

$104.49 +$1.43 (+1.39%) 1D After hours
Session Pulse After hours chatter is louder than usual 1 mentions today No new SEC filings since Tue close its sector ranked 5/11 this week Full pulse →
Charting by TradingView

Key Metrics

$179.51B
Market cap
28.60×
P/E · TTM
$45.13B
Revenue · TTM
$6.28B
Net income
EPS · TTM $3.59
Dividend yield 2.3%
Free cash flow $7.38B
Beta · 1Y 0.08
EBITDA · TTM $9.62B
Gross margin —

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    The stock moved +10.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 16
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 11
    From its Feb 27 high, the share price fell 29%.

    Peak close $116.35 on Feb 27; trough close $82.56 on May 11. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -29%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$179.51B
Enterprise value$205.17B
Shares outstanding1.7B
52-wk range$81.97 – $137.49
Avg volume · 20D6.3M
Net cash −$25.66B
Book value / share$29.80
IndustryPharmaceutical Preparations
ExchangeNYSE
About Abbott Laboratories
IPO dateApr 19, 1949
Employees115000

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E28.60
P/S3.98
P/FCF24.33
EV/EBITDA21.34
EV/Sales4.55
Graham №$49.07

Profitability

Gross —
Operating 18.0%
Net 13.9%
FCF 16.3%
ROE / ROIC 12.6% · 8.0%

Financial Health

Current ratio1.39
Quick ratio1.01
Debt / equity0.65
Debt / EBITDA 3.54
Net cash −$25.66B
Working capital$7.13B

Cash Flow · TTM

Operating CF $9.46B
Capex −$2.09B
Free cash flow $7.38B
Buybacks $793.00M
Dividends paid $4.19B
Shareholder yield 2.8%

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

—
Insufficient balance-sheet inputs

Graham Number vs Price

$49.07 vs $104.49
Trades 2.1× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings